Algeta ASA of Norway, which is developing a new treatment for hormone refractory prostate cancer called Alpharadin, has appointed Peter Harris as its chief medical officer.
Dr Harris will oversee the clinical development of Algeta’s oncology products, including Alpharadin, which is scheduled for a Phase 3 trial in 2008. Dr Harris previously was CMO of Oxigene Inc. He replaces Johan Harmenberg, who accepted a position of CEO of Axelar AB of Sweden, a portfolio company of Karolinska Development.
Sources:
Algeta press release, 14 September 2007
Copyright 2007 Evernow Publishing Ltd